文献速递慢阻肺呼吸道感染

重度慢阻肺长期阿奇霉素治疗超过一年的临床与安全性结局

Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment.
PubMed 文献 · Chest · 2018-02-07

该回顾性分析纳入109例GOLD D级重度慢阻肺患者,其中39例接受连续环状阿奇霉素(500mg每周三次)≥24个月。长期治疗组在12、24、36个月时急性加重分别减少56.2%、70%、41%,住院分别减少62.6%、75.8%、39.8%,但大环内酯类耐药增加50%。

要点

  • 长期阿奇霉素治疗可持续减少重度慢阻肺急性加重和住院超过50%。
  • 治疗24个月时急性加重减少70%,但36个月时降幅降至41%。
  • 大环内酯类耐药增加50%,需关注微生物学监测。

核心结论

  • 在GOLD D级重度慢阻肺患者中,24至36个月的长期连续环状阿奇霉素治疗可实现急性加重和住院的持续减少超过50%,且不良事件较少,但大环内酯类耐药增加。

研究设计与样本

  • 回顾性分析纳入109例GOLD D级重度慢阻肺患者,均有≥4次中重度急性加重且接受连续环状阿奇霉素(500mg每周三次)作为附加治疗,其中39例治疗≥24个月归为长期治疗组。

主要发现

  • 长期治疗组平均急性加重较基线减少:12个月56.2%、24个月70%、36个月41%。
  • 长期治疗组平均住院较基线减少:12个月62.6%、24个月75.8%、36个月39.8%。
  • 常见微生物所致急性加重在12和24个月分别下降12.5%和17.3%,大环内酯类耐药增加50%。
  • 铜绿假单胞菌急性加重在12和24个月分别上升7.2%和13.1%。
  • 不良反应少:短期消化系统紊乱7.1%,长期听力损失5.1%。

临床怎么用

  • 对于GOLD D级重度慢阻肺且频繁急性加重患者,可考虑长期连续环状阿奇霉素治疗,但需监测大环内酯类耐药和听力。

局限性

  • 本研究为回顾性分析,样本量有限,长期治疗组仅39例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exacerbations of COPD (ECOPD) are a major cause of mortality and morbidity. Continuous cyclic azithromycin (CC-A) reduces the exacerbation rate, but it is unknown whether it remains effective and safe beyond the first year. METHODS: This study was a retrospective analysis of patients with severe COPD (Global Initiative for Chronic Obstructive Lung Disease grade D) with ≥ 4 moderate to severe ECOPD who received CC-A (500 mg three times per week) as add-on therapy. Patients treated over 24 months were considered long-term continuous cyclic azithromycin (LT-CC-A) users, and ECOPD, hospitalizations, and length of hospital stays during the first, second, and third years were compared with the previous 12 months. Microbiologic monitoring, assessment of macrolide resistance, and analysis of side effects were maintained throughout the study period. RESULTS: A total of 109 patients with severe COPD treated with CC-A (39 for ≥ 24 months) comprised the LT-CC-A group (35.8%). This group presented average reductions in ECOPD from baseline of 56.2% at 12 months, 70% at 24 months, and 41% at 36 months, paralleled by respective reductions in hospitalizations of 62.6%, 75.8%, and 39.8%. ECOPD due to common microorganisms fell by 12.5% and 17.3% at 12 and 24 months of LT-CC-A, respectively, with a 50% increase in macrolide resistance. Pseudomonas aeruginosa ECOPD rose by 7.2% and 13.1% at these two time points. CC-A therapy was well tolerated with few side effects: digestive disorders in the short term (7.1%) and hearing loss in the long term (5.1%). CONCLUSIONS: LT-CC-A therapy over a 24- to 36-month period in patients with COPD (Global Initiative for Chronic Obstructive Lung Disease grade D) achieved sustained reductions in ECOPD and hospitalizations of > 50% with few adverse events, although macrolide resistance increased.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Pomares X, Montón C, Bullich M, et al. Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment. Chest. 2018. PMID: 29427576. doi:10.1016/j.chest.2018.01.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。